

Global NASH (Non –Alcoholics Steatohepatitis) Market 2017: Size, Share, Trends, Opportunities and Forecasts by 2030

WiseGuyReports.com adds “NASH (Non –Alcoholics Steatohepatitis) Market 2017 Global Analysis Research Report Forecasting to 2030” reports to its database.

PUNE, INDIA, August 14, 2017
/EINPresswire.com/ -- [NASH \(Non –Alcoholics Steatohepatitis\) Market:](#)

Executive Summary

Progressive numbers of Liver disorders along with rise in obesity will fuel the demand for NASH Drugs

The Global NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, untapped market with no FDA approved therapeutics. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyper Lipidemics are some of the off-label products currently used by NASH patients. Moreover, increase in number of patients suffering from fat in liver disorder is further anticipated to boost the Global NASH market in the coming years.

According to Analytics research report, “Global [NASH \(Non –Alcoholics Steatohepatitis\) Market: Trends, Opportunities and Forecasts \(2015-2030\) - \(By Region, By Drugs – Off Label & Special Treatment, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market\)](#)”, global non-alcoholic steatohepatitis drug specific market is estimated to start growing by 2020 at a CAGR of 25.56% during 2020-2030, due to the projected product launches in 2020. Surge in cycles of clinical trials and their success rate has improved the probability of industries receiving commercial approval for NASH therapeutics by the end of 2020. Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics. Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases. Despite of these challenges, certain key players such as Galmed Pharmaceuticals, Gilead Sciences, Novo Nordisk, Genfit, Intercept and Galectin Therapeutics are conducting extensive research on NASH therapeutics and are receiving positive results from clinical trials. But, the low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for these emerging players. The



United States, which has the highest number of research initiatives concerning NASH, holds nearly half of the global market share. The chief reason behind this growth is the high prevalence of diabetes and obesity and the growing number of people suffering with these conditions. The US has the highest number cases of NASH and other non-alcoholic fatty liver diseases.

Request Sample Report @ <https://www.wiseguyreports.com/sample-request/822692-global-nash-non-alcoholics-gft-505-market>

Scope of the Report

Global NASH (Non –Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) - (By Region, By Drugs – Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market) analyses the following aspects of global Alzheimer's market:

Global NASH Market Size, Share & Forecast
Segmental Analysis – By off Label , By Specific Drug and By Patient
Policy & Regulatory Landscape
Changing Market Trends & Emerging Opportunities
Competitive Landscape & Strategic Recommendations

Why You Should Buy This Report?

To gain an in-depth understanding of NASH disease and dementia market propelling globally.
To identify the on-going trends and anticipated growth in the next five years
To help industry consultants, drug and diagnostics manufacturers, vendors and dealers align their market-centric strategies
To obtain research based business decision and add weight to presentations and marketing material
To gain competitive knowledge of leading players
To avail limited customization in the report without any extra charges and get research data or trends added in the report as per the buyer's specific needs

Table of Content:-

Research Methodology
Executive Summary
Global NASH Market: An Analysis
3.1 Global NASH Market Overview
3.1.1 Global NAFLD Population
3.1.2 Global NASH Population
3.1.3 Global NASH Population, By Prevalence Rate
3.1.4 Global NASH Diagnosed Cases
3.2 Global NASH Market by Therapeutics
3.3 Global NASH Off-Label Drugs Market by Value
3.4 Global NASH Off-Label Drugs Market Share by Region
3.5 Global GFT505 Market: Sizing & Growth
3.5.1. GFT505 Estimated Valuation
3.5.2. GFT505 Market By Value
3.6. Global Aramchol Market: Sizing & Growth
3.6.1. Market Size: By Value
3.6.2. Market Size: By Patient Volume
3.7. Global GR-MD-02 Market: Sizing & Growth
3.7.1 GR-MD-02 in NASH Patients

3.7.2 GR-MD-02 Market By Value

Country Analysis

4.1 The US Nash Market Overview

4.1.1. The US NAFLD Population

4.1.2. THE US NASH Population

4.1.3. The US NASH Prevalence Rate

4.1.4. The US NASH Diagnosed Cases

4.1.5. The US NASH Treatment Rate

The US NASH Market by Therapeutics

5.1 The US NASH Off-Label Drugs Market by Value

5.2 The US NASH Specific Drugs Market by Value

5.3 The US Aramchol Market: Sizing & Growth

5.3.1. The US Aramchol Market: By Value

5.3.2. The US Aramchol Market: By Patient Volume

5.3.3. The US Aramchol Penetration Rate

5.3.4. Aramchol Cost of Treatment in the US

5.4 The US GFT505 Market by Value

5.4.1 The US GR-MD-02 Market: Sizing & Growth

5.4.2. GR-MD-02 Market By Value

5.4.3. GR-MD-02 Market by Patient Volume

5.4.4. GR-MD-02 Cost of Treatment in the US

Regional Analysis

6.1 Europe NASH Market Overview

6.1.1. Europe NAFLD Population

6.1.2. Europe NASH Population

6.1.3. Europe NASH Prevalence Rate

6.1.4. Europe NASH Diagnosed Cases

6.1.5. Europe NASH Treatment Rate

6.2 Europe NASH Market By Therapeutics

6.2.1. Europe NASH Off- Label Drugs Market By Value

6.2.2. Europe NASH Off- Label Drug Market Share By Region

6.2.3. Europe NASH Specific Drug Market By Value

6.3 Europe Aramchol Market: Sizing & Growth

6.3.1 Europe Aramchol Market By Value

6.3.2 Europe Aramchol Market By Patient Volume

6.3.3. Europe Aramchol Penetration Rate

6.3.4. Europe Aramchol Cost of Treatment

6.4 Europe NASH GFT 505 Market By Value

Country Overview

7.1. Japan NASH Market Overview

7.1.1. Japan NASH Therapeutics Market By Value.

Clinical Pipeline Analysis of NASH Drugs

8.1. Aramchol (Galmed)

8.1.2. Chemical Structure

8.1.3. Clinical Timeline

8.2. GFT505 (Genfit)

8.2.1 Chemical Structure

8.2.2 Clinical Timeline
8.2. Obeticholic acid or OCA (Intercept)
8.2.1 Chemical Structure
8.2.2 Clinical Timeline
8.2.3. Mechanism of Action
8.3. Cenicriviroc or CVC (Tobira Therapeutics)
8.3.1. Chemical Structure
8.3.2. Route Of Administration
8.3.3. Clinical Timeline
8.4 Cenicriviroc or CVC (Tobira Therapeutics)
8.4.1 Chemical Structure
8.4.2 Route Of Administration
8.4.3 Clinical Timeline

Market Dynamics
Competitive Landscape

...CONTINUED

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=822692

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.